Rationale: Several studies demonstrate that hematopoietic tissues are a source of endothelial progenitor cells, which contribute to newly formed blood vessels during tissue repair in adults. However, it is not clear which cell type in these hematopoietic tissues gives rise to endothelial progenitor cells.
I t has been hypothesized that endothelial progenitor cells (EPCs) reside in adult bone marrow (BM) and are mobilized into peripheral circulation by cytokines or tissue ischemia. 1, 2 Transplantation of either culture-expanded EPCs or freshly isolated cells from adult hematopoietic sources results in enhanced blood-flow 3 and improved function of ischemic tissues. 4 -10 However, engraftment levels vary significantly from laboratory to laboratory. This variability could be attributable to the heterogeneity of vascular precursor populations identified in hematopoietic tissues, as well as differences in experimental design. To date, controversy still exists with respect to the identification and the origin of these precursors in hematopoietic tissues. For instance, a number of cell types obtained using different strategies have been referred to as EPCs, including differentiated endothelial cells with more limited proliferation ability, [11] [12] [13] and cells associated with the myelomonocytic lineage. 14 -16 Although several investigators still use the whole mononuclear cell fraction to study postnatal revascularization, 14, 17 a number of surface markers have been shown to be useful to identify endothelial progenitors in hematopoietic tissues. EPCs were first isolated from peripheral blood using antibodies to VEGFR-2 (KDR) or CD34. 4 Although expression of KDR in hematopoietic tissues is controversial, CD34 has found common use as a marker for isolating EPCs. 3, 7, 9 Although it is clear that CD34 purification enriches for EPCs, CD34 by itself is not a particularly good marker because it is also expressed in hematopoietic stem cells (HSCs), 18 multiple hematopoietic progenitor cells, 19 and mature circulating endothelial cells (ECs). 20 The hematopoietic stem cell marker CD133 21 has been suggested to provide better enrichment for endothelial progenitors because it is expressed on EPCs but downregulated in mature endothelial cells. 22 Consistently, a number of studies support the premise that the CD133 ϩ cell fraction is enriched for EPCs 23 and provide evidence for superior perfusion following their transplantation in animal models of ischemia. 24, 25 However, because CD133 is also present in early hematopoietic progenitors, 21 phenotypic distinction between hematopoietic and endothelial progenitors is not possible. To make things more complicated, 2 recent studies argue that CD133 ϩ cells do not possess the ability to generate endothelial cells. 26, 27 Therefore, to date, the origin of endothelial progenitors within the hematopoietic hierarchy remains controversial.
This study was designed to assess whether hematopoietic progenitors, in particular CD133 ϩ , have the ability to differentiate into endothelial cells. To rule out the existence of independent progenitors for hematopoietic and endothelial lineages within the CD133 compartment, we tested for the presence of a common precursor at the single cell level. In this way, one can characterize both the single starting cell and its specific progeny. By using single-cell sorting assays in combination with replating studies in multiple cord blood samples, here we show the existence of a cell endowed with the ability to differentiate toward the endothelial, myeloid, and lymphoid lineages.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Sample Collection and Purification
Samples of umbilical cord blood (UCB) from healthy term newborns were obtained according to procedures approved by the institutional review boards of University of Texas Southwestern Medical Center and University of Minnesota. Mononuclear cells (MNCs) were isolated by Ficoll-Hypaque density-gradient centrifugation. In most cases, before fluorescence-activated cell (FACS), cells were preenriched for CD34 using MACS magnetic beads. Detailed purification approach is described in the Online Data Supplement.
Clonal Analysis and Evaluation of Multipotentiality
Single CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells were seeded in proliferation medium containing VEGF, SCF, and TPO. After 1 week, resulting colonies were divided into 4 subfractions and then subcultured in specific conditions to assess their ability to differentiate into endothelial, myeloid, T-and B-lymphoid lineages. Differentiation and characterization procedures are described in detail in the Online Data Supplement.
Matrigel Plug Assay and Hindlimb Ischemia Model
NOD-scid IL2R␥ null mice (The Jackson Laboratory) were used as recipients. Animal care and all procedures were performed according to University of Minnesota Institutional Animal Care & Usage Guidelines. Detailed information regarding these procedures, as well as analyses of engraftment and laser Doppler perfusion imaging, are described in the Online Data Supplement.
Results
Endothelial Potential Is Restricted to the CD34 ؉ CD45 ؉ CD133 ؉ CD38 ؉ Cell Fraction
We began by subfractionating the CD34 ϩ CD133 ϩ fraction from UCB based on CD38 and CD45 expression. As observed in Figure 1A (and Online Figure I) , the large majority of CD34 ϩ CD45 ϩ CD133 ϩ cells coexpress CD38. The ability of this early hematopoietic cell population to generate endothelial precursors in vitro was assessed side-by-side with more committed hematopoietic cell types, including CD33 ϩ (myeloid progenitors) ( Figure 1B ) and CD14 ϩ (monocytes/ macrophages) ( Figure 1C ). CD33 ϩ and CD14 ϩ cells adhered to the plastic dish when cultured under endothelial conditions, displayed a spindle endothelial-like phenotype by week 2, but failed to expand under these culture conditions ( Figure 1D ). On the other hand, the CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cell fraction proliferated considerably and eventually gave rise to an endothelial-like cell population, which emerged after 4 to 6 weeks in culture ( Figure 1D and 1E), that resembled human umbilical vein endothelial cells (HUVECs) ( Figure 1F ). The endothelial phenotype of these cells was confirmed by the expression of VE-cadherin, von Willebrand factor (vWF), KDR, and to a lesser extent endothelial nitric oxide synthase ( Figure 1H ). These endothelial markers were first detected by week 3, and were abundant by week 6 ( Figure 1H ), whereas hematopoietic markers were significantly downregulated by this time ( Figure 1G ).
Myeloid, and Lymphoid Potential
To dissect the multi-lineage differentiation potential of this cell fraction, clonal analysis was performed by FACS single cell sorting ( Figure 2 ). Clones derived from CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ single cells (85 from a total of 1024 wells, cloning efficiency of 8.2%) were expanded for 1 week, and each divided into 4 fractions for endothelial, myeloid as well as T-and B-lymphoid cell growth ( Figure 2 ).
Our results showed that 49.5% of obtained clones (42 from a total of 85 clones) derived from the CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ population were able to produce all 4 lineages ( Figure  3A) , as confirmed by detailed characterization of these clones. Several myeloid colonies were detected following the replating of one-fourth of the cells from each clone in complete hematopoietic methylcellulose medium ( Figure 3B ). To determine the capacity of these clones to differentiate into T and B lymphocytes in vitro, the second and third parts of these colonies were cultured on OP9-DL1 28 and MS-5 29 stromal cells, respectively. The presence of B lymphocytes was demonstrated by expression of CD19 and IgM after culture on MS-5 for 45 days ( Figure 3C ). Lineage-specific differentiation was further confirmed by a PCR assay for DJ and VDJ recombination at the immunoglobulin heavy chain locus ( Figure 3C ). Likewise, double positive CD4 ϩ CD8 ϩ T lymphocytes were observed after 45 days in culture on OP9-DL1 ( Figure 3D ). To assess whether these clonal-derived lymphocytes were capable of undergoing T-cell activation, day 45 expanding CD4 ϩ CD8 ϩ T lymphocytes were stimulated with IL-2, anti-CD3 and anti-CD28 antibodies for 5 days. 28 At this time, cells became CD27 ϩ CD69 ϩ , a phenotype characteristic of activated T-cells, whereas before stimulation, these markers were absent ( Figure 3D ).
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Consistent with the initial results ( Figure 1 ), CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ -derived clones yielded a monolayer of proliferating cells in the presence of endothelial cell growth medium (resulting from one fourth of original clone; Figure 2 ). The endothelial nature of these cells expanded for 4 to 5 weeks was confirmed by FACS analysis which revealed the expression of CD146, CD144 (VE-cadherin), and KDR, as well as the lack of CD45 and CD14 ( Figure 4A ; a total of 42 endothelial cultures were analyzed and all displayed similar results). The majority of these cells coexpressed KDR and CD146 ( Figure 4B ), confirming their endothelial phenotype. Further immunostaining analysis demonstrated coexpression of vWF and VE-cadherin in expanded endothelial cells ( Figure 4C ). When cultured in Matrigel, these clonal-derived monolayer cells were capable of generating extensive capillary-like structures ( Figure 4D ). 
, and CD14 ϩ (C) cells isolated from UCB. A, UCB MNCs were preenriched for CD34 with magnetic beads and further purified by FACS based on CD45, CD133, and CD38 expression. Left, Fluorescence intensity of APClabeled CD34 (y axis) and FITC-labeled CD45 (x axis). Ellipse represents cell fraction gated for phycoerythrin (PE)-labeled CD133 (y axis) and PE-Cy7-conjugated CD38 (x axis), which is represented in the right graph. Percentages represent the fraction of cells that express a given surface antigen. B and C, MNCs were stained with FITC-labeled CD33 and APC-conjugated CD14 antibodies, respectively. In these graphs, y axis represents PE, which provides a measure of autofluorescence. Solid squares represent cell gates for sorting. D, Morphological aspect of sorted cells, initially plated at 10 5 /cm 2 , expanded for 1 week in proliferation medium (left), and then switched to endothelial specific medium at week 2, week 4, and week 6 (E); HUVECs as reference (F). Gene expression analysis of CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ -derived cell cultures for hematopoietic (G) and endothelial (H) markers. Transcripts are normalized to GAPDH.
Additionally, we performed quantitative gene expression analysis to further confirm the endothelial, and nonhematopoietic, nature of these clones. Accordingly, high levels of KDR, vWF, VE-cadherin and endothelial nitric oxide synthase were detected in CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩderived endothelial clones, similarly to control HUVECs ( Figure 4E ). On the other hand, hematopoietic markers, including CD45, CD133 and c-fms, the receptor for macrophage colony-stimulating factor, were absent ( Figure 4F ), confirming the nonhematopoietic nature of these cells. Because CD41 and Runx-1 have been associated with the emergence of hematopoietic cells from endothelial cells 30 -33 during development, a process known as hemogenic endothelium, we also investigated the expression levels for these genes in CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ -derived endothelial clones and their freshly isolated hematopoietic counterparts.
CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells, before EC differentiation, were found to express much higher levels of CD41 and Runx-1 (Online Figure II) than their respective endothelial cell clones. We also followed the expansion potential of CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ -derived endothelial progenitor clones (a total of 20 clones). These cells were amenable to expansion, reaching their growth peak at Ϸ50 days, at which point, senescence occurred (Online Figure II) .
Cells Improve Perfusion in Ischemic Mice
To examine whether transplantation of CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells would increase vascularization in the ischemic hindlimb of NOD-scid IL2R␥ null mice that had been subjected to femoral artery ligation, freshly purified CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells (3ϫ10 5 ) were locally transplanted into Figure 2 . Scheme for single-cell assays. CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells were single-cell sorted and expanded in proliferation medium. After 1 week, each resulting colony was divided into 4 subfractions, and then subcultured in specific conditions for endothelial, myeloid, T-lymphoid, and B-lymphoid cell growth. Photographs were taken at ϫ20. the ischemic thigh muscle area immediately after surgery at 3 different injection points. Control groups consisted of mice receiving the same number of MNCs or simply PBS. Serial analyses with Laser Doppler Perfusion Imaging (LDPI) revealed superior vascularization in mice that had been treated with CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells ( Figure 5A ). Accordingly, the ratio of the ischemic/nonischemic hindlimb blood flow in the CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ -transplanted group was increased when compared with PBS-or MNC-treated mice at postoperative days 21 and 28 ( Figure 5B ).
CD34 ؉ CD45 ؉ CD133 ؉ CD38 ؉ Cells Rarely Differentiate Into Endothelial Cells in Ischemic Mice
One month after the transplantation, mice were analyzed for the presence of human cells by immunofluorescence staining. We performed double staining with human and mouse specific anti-CD31 antibodies to best discriminate recipientversus donor-derived vessels, as well as to identify chimeric vessels. As expected, all control mice injected with PBS (nϭ7) stained only with mouse CD31, similar to the control muscle staining (Online Figure III) . In the group of mice that had received MNCs, we were able to detect human cells in 4 of 7 mice; however most of these mice presented only a few CD31 ϩ cells in 1 or 2 areas of the injected muscle (Online Figure IV) , a finding that supports the lack of perfusion improvement in mice transplanted with MNCs ( Figure 5A and 5B). Although human CD31 ϩ cells were easily detected in most of the mice transplanted with CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells (7 of 8), we found only one chimeric vessel (one chimeric vessel in 1 of 7 engrafted mice) ( Figure  5C ). The majority of engrafted human CD31 ϩ cells were found surrounding the recipient vessels ( Figure 5D ), a pattern observed in all transplanted mice. We observed that the majority of the human CD31 ϩ cells surrounding the recipient vessels maintained expression of CD45 ϩ (Figure 5E ). These results indicate that the endothelial differentiation of this progenitor is compromised in the xenogeneic environment, and that contribution of human cells to improved perfusion was not attributable to donor-derived vasculogenesis, but possibly to a paracrine mechanism.
Endothelial Cells Derived From the CD34 ؉ CD45 ؉ CD133 ؉ CD38 ؉ Cell Fraction Participate in Neovascularization In Vivo
To assess whether the ischemic model does not favor the in vivo differentiation of CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells into endothelial cells, we differentiated them first in vitro into endothelial cells ( Figure 6A and 6B) , and injected these into mice using the Matrigel plug assay. Two weeks after implan- tation, plugs were removed and analyzed by immunofluorescence staining for human and mouse CD31. In the case of freshly isolated cells, we observed again the presence of human CD31 ϩ cells surrounding the mouse-derived vessels or alternatively, as clusters of hematopoietic cells (Online Figure V) . In contrast, plugs that were injected with CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ -derived endothelial cells presented both donor-and recipient-derived vessels ( Figure 6C and 6D), as indicated by staining with human-and mousespecific anti-CD31 antibodies ( Figure 6E and 6G [human] and 6F [mouse], respectively). These newly formed vessels were functional as evidenced by the presence of erythrocytes in the lumen (Figure 6C through 6G) .
Based on these findings, we investigated the ability of CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ -derived endothelial cells to contribute to new vessels in the ischemic hindlimb model. To confirm the functionality of human-derived endothelial cells, biotinylated tomato lectin, which specifically binds to perfused endothelial cells, was injected intravenously into transplanted mice just before euthanasia. As observed in Figure 7 , functional human-derived blood vessels were integrated into the host circulatory system, as demonstrated by costaining for Figure 5 . In vivo potential of CD34 ؉ CD45 ؉ CD133 ؉ CD38 ؉ cells in hindlimb ischemic mice. A, Representative Doppler analysis of mice transplanted with CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells, MNCs, and PBS control groups. In these digital color-coded images, red indicates regions with maximum perfusion; medium perfusion values are shown in yellow; lowest perfusion values are represented in blue. B, Comparison of perfusion recovery in hindlimb ischemic mice transplanted with PBS (A) , MNCs (B) , and CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells (C) (10 mice per group). Color-coded recordings were analyzed by calculating the average perfusion for each leg (ischemic and nonischemic). Perfusion is expressed as ratio of left (ischemic) and right (nonischemic) legs. Data are expressed as meansϮSD. *PϽ0.05. C, Immunofluorescence staining of transplanted muscle sections with human (red) and mouse (green) specific CD31 antibodies shows a chimeric vessel. D, Same staining of a different muscle section shows a distinct pattern, in which human CD31 ϩ cells (red) are located nearby recipient's blood vessels (green). E, Immunofluorescence staining reveals that human CD31 ϩ cells (red) coexpress CD45 (green). DAPI staining is shown in blue.
Lectin and CD31. These results confirm the endothelial nature of the endothelial cells that were differentiated from the common progenitor, the CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cell fraction.
Discussion
The identification of endothelial progenitors in the adult circulation by Asahara et al 4 has challenged the dogma that vasculogenesis is restricted to embryogenesis. Adult endothelial progenitors are found in association with the hematopoietic compartment. 1, 2 However whether endothelial and hematopoietic progenitors have a common origin or represent independent lineages within the bone marrow remains a topic of debate. Interestingly, a study involving the analysis of blood and bone marrow samples obtained from chronic myeloid leukemia revealed the presence of BCR/ABL, the oncoprotein encoded by the Philadelphia chromosome, in both hematopoietic and endothelial cells. 34 This is particularly relevant because detection of the Philadelphia chromo-some in all blood lineages of individuals with chronic myeloid leukemia has been considered as direct evidence for the existence of the HSC in humans. 35 Stronger evidence for an association between these 2 lineages in postnatal life was provided by Grant and colleagues. 36 By transplanting individual Sca-1 ϩ c-Kit ϩ Lin Ϫ BM HSCs from GFP transgenic mice into irradiated recipients, these authors demonstrated that on hematopoietic engraftment, donor-derived GFP ϩ cells contributed to the endothelial lineage when mice were subjected to retinal ischemia. 36 Similar results were observed following the transplantation of cord blood CD34 ϩ cells into NOD/scid mice. 36a These results were corroborated by another study demonstrating that infusion of individual Sca-1 ϩ c-Kit ϩ Lin Ϫ BM HSCs resulted in broad incorporation of donor-derived cells into the endothelial compartment even in the absence of additional vascular injury, which was not a result of cell fusion. 37 Further studies by this group suggest that endothelial engraftment resulted from the stem cell pool or from a common myeloid progenitor but not from a Figure 6 . In vivo revascularization potential of CD34 ؉ CD45 ؉ CD133 ؉ CD38 ؉ -derived endothelial clones using the Matrigel plug assay. A, Morphology of a representative endothelial clone that was used for these studies. B, Quantitative PCR analysis of these endothelial cells before transplantation confirms their endothelial nature. HUVECs were used as reference. Transcripts are normalized to GAPDH. C, Hematoxylin/eosin staining shows a cross-section of a vascularized Matrigel plug containing functional blood vessels, as evidenced by the presence of erythrocytes in the lumen. D, Immunofluorescence staining of the same section for humanand mouse-specific CD31 antibodies. Bright field is shown in the far left image as reference. White square indicates a donor-derived blood vessel at the center of Matrigel, as evidenced by the expression of human CD31 (in red), whereas white circle indicates a recipient-derived blood vessel located at the border of the Matrigel, which is positive for mouse CD31 (in green). Red arrows on bright field image indicate the presence of RBCs inside vessels. E and F, Highermagnification images of humanderived (E) and mouse-derived (F) blood vessels that are shown in D. White arrow in F shows a hybrid small capillary containing human and mouse cells. G, High magnification of another human-derived blood vessel. Red arrow in the merged image (far right) shows RBCs in the lumen of vessel. lymphoid progenitor. 38 Although all these findings support the hypothesis that endothelial progenitors arise within the hematopoietic compartment, it is still unclear which cell type in the hematopoietic hierarchy gives rise to the endothelial lineage.
By using a combination of surface markers, single cell sorting assays, and subsequent replating studies, here we demonstrate for the first time, the existence of an adult common precursor for endothelial, myeloid, and lymphoid progenitors in human cord blood. Unexpectedly, this bipotent precursor resides within the CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ fraction, downstream of CD34 ϩ CD38cells, suggesting that a multipotent progenitor, not the hematopoietic stem cell, is the point of divergence of the endothelial and hematopoietic lineages.
Despite the evident ability of CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells to differentiate into hematopoietic and endothelial cells in vitro, hematopoietic differentiation predominates in ischemic transplantation. This may be due to the mouse environment, which is not appropriate or sufficient to induce the differentiation of this human precursor into endothelial cells.
Because our goal here was to investigate whether hematopoietic cells, in particular CD133 ϩ , have the ability to differentiate into endothelial cells, we did not address the existence of other angiogenic cells outside of the hematopoietic compartment, as suggested by other investigators. 26, 27, 39 Mouse-to-mouse transplantation experiments involving the analyses of mice that had been subjected to unilateral femoral artery occlusion following the engraftment of BM cells isolated from transgenic mice expressing enhanced green fluorescent protein (GFP) revealed that donor GFP ϩ cells fail to incorporate into the adult growing vasculature, but were detectable around growing collateral arteries. 40 A similar outcome was obtained following the transplantation of hematopoietic stem cells isolated from GFP transgenic mice directly into ischemic myocardium of wild-type mice. 41 Interestingly here we observed a similar engraftment pattern following the transplantation of freshly isolated CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells into hindlimb ischemic mice. In these engrafted mice, human CD31 ϩ CD45 ϩ cells were found in large quantities surrounding recipient's vasculature, suggesting that the improved perfusion observed in transplanted mice may be mostly attributable to a paracrine proangiogenic function of these cells. This would be in agreement with recent studies involving the transplantation of human CD133 ϩ cells 42, 43 or EPCs, 44, 45 which indicate that these cell types secrete angiogenic factors. 40, 44 On the other hand, when CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cells are allowed to differentiate into endothelial cells in vitro, and then injected into mice using the Matrigel plug assay or the ischemia model, these cells give rise to functional human-derived and chimeric mouse-human blood vessels. Taken together, our data reveal that the CD34 ϩ CD45 ϩ CD133 ϩ CD38 ϩ cell fraction, which per se may have an angiogenic effect in vivo, is endowed with the ability to differentiate in vitro into myeloid, lymphoid, and endothelial lineages. The endothelial cells generated from this common precursor are able to participate in new blood vessel formation, providing a rationale for the use of this cell population, as well as their progenitor, for therapeutic applications in ischemia conditions. Figure 7 . In vivo revascularization potential of CD34 ؉ CD45 ؉ CD133 ؉ CD38 ؉ -derived endothelial clones in hindlimb ischemic mice. A, High magnification of a newly formed human-derived capillary vessel (white arrow), which coexpresses human CD31 (in red) and lectin (in green). This vessel sits close to a recipient-derived vessel, which is Lectin ϩ and negative for human CD31 (green arrow). B, High magnification of a hybrid blood vessel. CD31 staining reveals the incorporation of human CD31 ϩ cells in a vessel that homogenously express lectin (in green) and vWF (in purple), which labels both mouse and human cells. Merged images show coexpression of human CD31 with lectin and vWF, as indicated by white arrows.
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